

Ivelin S Georgiev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5416874/publications.pdf>

Version: 2024-02-01

41
papers

6,001
citations

257101

24
h-index

276539

41
g-index

44
all docs

44
docs citations

44
times ranked

5542
citing authors

#	ARTICLE	IF	CITATIONS
1	Sequence and functional characterization of a public HIV-specific antibody clonotype. <i>IScience</i> , 2022, 25, 103564.	1.9	1
2	Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. <i>Nature Biotechnology</i> , 2022, 40, 1270-1275.	9.4	27
3	High-Throughput B Cell Epitope Determination by Next-Generation Sequencing. <i>Frontiers in Immunology</i> , 2022, 13, 855772.	2.2	7
4	An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	14
5	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
6	B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 564-578.e9.	5.1	18
7	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021, 2, 100313.	3.3	56
8	Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. <i>Viruses</i> , 2021, 13, 1296.	1.5	3
9	Simultaneous Immunization with Multiple Diverse Immunogens Alters Development of Antigen-Specific Antibody-Mediated Immunity. <i>Vaccines</i> , 2021, 9, 964.	2.1	2
10	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. <i>Cell Reports</i> , 2021, 37, 109784.	2.9	20
11	Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 670561.	2.2	3
12	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains. <i>Journal of Infectious Diseases</i> , 2020, 221, 756-765.	1.9	2
13	Spontaneous Glycan Reattachment Following N-Glycanase Treatment of Influenza and HIV Vaccine Antigens. <i>Journal of Proteome Research</i> , 2020, 19, 733-743.	1.8	5
14	Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease. <i>Science Immunology</i> , 2020, 5, .	5.6	32
15	Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. <i>Virology</i> , 2020, 546, 1-12.	1.1	5
16	Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. <i>Nature Medicine</i> , 2020, 26, 228-235.	15.2	61
17	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , 2020, 16, e1009101.	2.1	13
18	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	6.6	85

#	ARTICLE	IF	CITATIONS
19	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	6.6	77
20	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. <i>PLoS Computational Biology</i> , 2019, 15, e1006952.	1.5	25
21	NFPws: a web server for delineating broadly neutralizing antibody specificities from serum HIV-1 neutralization data. <i>Bioinformatics</i> , 2019, 35, 3502-3504.	1.8	5
22	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. <i>Cell</i> , 2019, 179, 1636-1646.e15.	13.5	219
23	A Neutralizing Antibody Recognizing Primarily N-Linked Glycan Targets the Silent Face of the HIV Envelope. <i>Immunity</i> , 2018, 48, 500-513.e6.	6.6	66
24	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018, 24, 857-867.	15.2	256
25	Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. <i>Cell Host and Microbe</i> , 2018, 23, 845-854.e6.	5.1	100
26	Antibodyomics: bioinformatics technologies for understanding B cell immunity to HIV-1. <i>Immunological Reviews</i> , 2017, 275, 108-128.	2.8	32
27	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. <i>Immunity</i> , 2017, 46, 777-791.e10.	6.6	81
28	Antibacterial photosensitization through activation of coproporphyrinogen oxidase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6652-E6659.	3.3	18
29	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017, 13, e1006148.	2.1	51
30	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. <i>Cell</i> , 2016, 165, 813-826.	13.5	379
31	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016, 352, 828-833.	6.0	310
32	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016, 166, 609-623.	13.5	270
33	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. <i>Immunity</i> , 2016, 45, 1108-1121.	6.6	304
34	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	13.5	305
35	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	13.5	305
36	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	13.7	681

#	ARTICLE	IF	CITATIONS
37	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	13.7	702
38	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature, 2014, 515, 138-142.	13.7	400
39	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science, 2013, 340, 751-756.	6.0	213
40	Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Current Opinion in HIV and AIDS, 2013, 8, 382-392.	1.5	27
41	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science, 2011, 333, 1593-1602.	6.0	788